Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Gilead's commercial success underscores the dedication ... a first-in-class capsid inhibitor that was recently recognized by science as 2024's breakthrough of the year. To put this in context ...

Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis ... has confirmed that Kite's R&D as well as its commercial operations will remain based in ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration approval, with a decision expected in mid-June, Gilead Sciences Inc. announced ...

Gilead Sciences Inc. GILD stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being asleep for so many years, the stock has finally found ...

Gilead's commercial success underscores the dedication ... a first-in-class capsid inhibitor that was recently recognized by science as 2024's breakthrough of the year. To put this in context ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full ... Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Dietmar Berger; and our ...